SOLTI-1805 TOT-HER3 Study Concept: A Window-of-Opportunity Trial of Patritumab Deruxtecan, a HER3 Directed Antibody Drug Conjugate, in Patients With Early Breast Cancer

SOLTI-1805 TOT-HER3 Study Concept: A Window-of-Opportunity Trial of Patritumab Deruxtecan, a HER3 Directed Antibody Drug Conjugate, in Patients With Early Breast Cancer

Background: Preclinical data support a key role for the human epidermal growth factor receptor 3 (HER3) pathway in hormone receptor (HR)–positive breast cancer. Recently, new HER3 directed antibody drug conjugates have shown activity in breast cancer. Given the need to better understand the molecula...

Ամբողջական նկարագրություն

Մատենագիտական մանրամասներ
Հիմնական հեղինակներ:	Tomás Pascual, Mafalda Oliveira, Eva Ciruelos, Meritxell Bellet Ezquerra, Cristina Saura, Joaquin Gavilá, Sonia Pernas, Montserrat Muñoz, Maria J. Vidal, Mireia Margelí Vila, Juan M. Cejalvo, Blanca González-Farré, Martin Espinosa-Bravo, Josefina Cruz, Francisco Javier Salvador-Bofill, Juan Antonio Guerra, Ana María Luna Barrera, Miriam Arumi de Dios, Stephen Esker, Pang-Dian Fan, Olga Martínez-Sáez, Guillermo Villacampa, Laia Paré, Juan M. Ferrero-Cafiero, Patricia Villagrasa, Aleix Prat
Ձևաչափ:	Հոդված
Լեզու:	English
Հրապարակվել է:	Frontiers Media S.A. 2021-04-01
Շարք:	Frontiers in Oncology
Խորագրեր:	Breast Cancer ERBB3 HER3 U3-1402 patritumab deruxtecan HER3-DXd
Առցանց հասանելիություն:	https://www.frontiersin.org/articles/10.3389/fonc.2021.638482/full

Նմանատիպ նյութեր

Intrinsic subtypes and therapeutic decision-making in hormone receptor-positive/HER2-negative metastatic breast cancer with visceral crisis: A case report
‌: Francesco Schettini, և այլն
Հրապարակվել է: (2022-11-01)

Dissecting the biological heterogeneity of HER2-positive breast cancer
‌: Francesco Schettini, և այլն
Հրապարակվել է: (2021-10-01)

Oestrogen receptor activity in hormone-dependent breast cancer during chemotherapy
‌: Nuria Chic, և այլն
Հրապարակվել է: (2021-07-01)

HOPE (SOLTI-1903) breast cancer study: real-world, patient-centric, clinical practice study to assess the impact of genomic data on next treatment decision-choice in patients with locally advanced or metastatic breast cancer
‌: Rubén Olivera-Salguero, և այլն
Հրապարակվել է: (2023-04-01)

First Nationwide Molecular Screening Program in Spain for Patients With Advanced Breast Cancer: Results From the AGATA SOLTI-1301 Study
‌: Sonia Pernas, և այլն
Հրապարակվել է: (2021-11-01)

Gene expression profiles of breast cancer metastasis according to organ site
‌: Fara Brasó‐Maristany, և այլն
Հրապարակվել է: (2022-01-01)

Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancer
‌: Gaia Griguolo, և այլն
Հրապարակվել է: (2019-03-01)

Case Report: A Case Study Documenting the Activity of Atezolizumab in a PD-L1-Negative Triple-Negative Breast Cancer
‌: Fara Brasó-Maristany, և այլն
Հրապարակվել է: (2021-09-01)

Cell-cycle inhibition and immune microenvironment in breast cancer treated with ribociclib and letrozole or chemotherapy
‌: Tomás Pascual, և այլն
Հրապարակվել է: (2024-03-01)

“Positioning of tucatinib in the new clinical scenario of HER2-positive metastatic breast cancer: An Italian and Spanish consensus paper”
‌: Pierfranco Conte, և այլն
Հրապարակվել է: (2024-08-01)

Frequency and spectrum of PIK3CA somatic mutations in breast cancer
‌: Olga Martínez-Sáez, և այլն
Հրապարակվել է: (2020-05-01)

Circulating tumor DNA reveals complex biological features with clinical relevance in metastatic breast cancer
‌: Aleix Prat, և այլն
Հրապարակվել է: (2023-03-01)

Oral metronomic vinorelbine combined with endocrine therapy in hormone receptor-positive HER2-negative breast cancer: SOLTI-1501 VENTANA window of opportunity trial
‌: Barbara Adamo, և այլն
Հրապարակվել է: (2019-09-01)

Targeting HER 1 and 2 in breast cancer with lapatinib
‌: Gerald M. Higa
Հրապարակվել է: (2011-12-01)

Targeting HER 1 and 2 in breast cancer with lapatinib
‌: Gerald M. Higa
Հրապարակվել է: (2011-12-01)

Nuclear HER3 expression improves the prognostic stratification of patients with HER1 positive advanced laryngeal squamous cell carcinoma
‌: Giovanni Almadori, և այլն
Հրապարակվել է: (2021-09-01)

Targeting the EGF receptor family in non-small cell lung cancer—increased complexity and future perspectives
‌: Tobias Boch, և այլն
Հրապարակվել է: (2022-11-01)

The effects of trastuzumab on HER2-mediated cell signaling in CHO cells expressing human HER2
‌: Hamid Maadi, և այլն
Հրապարակվել է: (2018-03-01)

Anti-tumoral activity of the Pan-HER (Sym013) antibody mixture in gemcitabine-resistant pancreatic cancer models
‌: Emilia Rabia, և այլն
Հրապարակվել է: (2021-01-01)

Expression of EGFR isoform D is regulated by HER receptor activators in breast cancer cells
‌: Lisandra Negrón-Vega, և այլն
Հրապարակվել է: (2022-09-01)

Editorial: Cancer Treatment and Early Detection Targeting HER Receptors
‌: Xiaoqing Cai, և այլն
Հրապարակվել է: (2022-06-01)

HER3 targeting with an antibody‐drug conjugate bypasses resistance to anti‐HER2 therapies
‌: Lucía Gandullo‐Sánchez, և այլն
Հրապարակվել է: (2020-04-01)

Editorial: Cancer treatment and early detection targeting HER receptors, Volume II
‌: Xiaoqing Cai, և այլն
Հրապարակվել է: (2023-06-01)

NRG1 Fusions in NSCLC: Being eNRGy Conscious
‌: Gupta B, և այլն
Հրապարակվել է: (2024-10-01)

A Preliminary Evaluation of the Prognostic Role of HER-2 and HER-3 Immunohistochemical Expression in Canine Melanomas
‌: Francesca Parisi, և այլն
Հրապարակվել է: (2024-05-01)

Yap governs a lineage-specific neuregulin1 pathway-driven adaptive resistance to RAF kinase inhibitors
‌: Maria E. R. Garcia-Rendueles, և այլն
Հրապարակվել է: (2022-12-01)

Combined targeting of HER-2 and HER-3 represents a promising therapeutic strategy in colorectal cancer
‌: Lena-Christin Conradi, և այլն
Հրապարակվել է: (2019-09-01)

Positive prognostic value of HER2-HER3 co-expression and p-mTOR in gastric cancer patients
‌: Guo-dong Cao, և այլն
Հրապարակվել է: (2017-12-01)

HER2DX genomic test in HER2-positive/hormone receptor-positive breast cancer treated with neoadjuvant trastuzumab and pertuzumab: A correlative analysis from the PerELISA trialResearch in context
‌: Valentina Guarneri, և այլն
Հրապարակվել է: (2022-11-01)

A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer
‌: Kerry Lynn Reynolds, և այլն
Հրապարակվել է: (2017-09-01)

Inhibitor-induced HER2-HER3 heterodimerisation promotes proliferation through a novel dimer interface
‌: Jeroen Claus, և այլն
Հրապարակվել է: (2018-05-01)

Patritumab deruxtecan in HER2-negative breast cancer: part B results of the window-of-opportunity SOLTI-1805 TOT-HER3 trial and biological determinants of early response
‌: Fara Brasó-Maristany, և այլն
Հրապարակվել է: (2024-07-01)

Palbociclib and letrozole for hormone receptor-positive HER2-negative breast cancer with residual disease after neoadjuvant chemotherapy
‌: Sonia Pernas, և այլն
Հրապարակվել է: (2024-11-01)

New era for emerging therapeutic targeting human epidermal growth factor receptor 3 (HER 3) in advanced nonsmall cell lung cancer and metastatic breast cancer
‌: Yasar Ahmed, և այլն
Հրապարակվել է: (2022-09-01)

Influence of Molecular Design on the Targeting Properties of ABD-Fused Mono- and Bi-Valent Anti-HER3 Affibody Therapeutic Constructs
‌: Mohamed Altai, և այլն
Հրապարակվել է: (2018-10-01)

HER3 signaling and targeted therapy in cancer
‌: Rosalin Mishra, և այլն
Հրապարակվել է: (2018-05-01)

Induction of SUSD2 by STAT3 Activation Is Associated with Tumor Recurrence in HER2-Positive Breast Cancer
‌: Yisun Jeong, և այլն
Հրապարակվել է: (2024-12-01)

Systems Analysis of Drug-Induced Receptor Tyrosine Kinase Reprogramming Following Targeted Mono- and Combination Anti-Cancer Therapy
‌: Alexey Goltsov, և այլն
Հրապարակվել է: (2014-06-01)

Sortilin‐related receptor is a druggable therapeutic target in breast cancer
‌: Hussein Al‐Akhrass, և այլն
Հրապարակվել է: (2022-01-01)

A Standardized Wedelia chinensis Extract Overcomes the Feedback Activation of HER2/3 Signaling upon Androgen-Ablation in Prostate Cancer
‌: Chin-Hsien Tsai, և այլն
Հրապարակվել է: (2017-10-01)